3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
12
Non-Muscle Invasive Bladder Neoplasms
4
Recurrence
2
Lung Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
BCG Vaccine
×
Clear all
NCT05037279
2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3
Recruiting
540 enrolled
NCT03664869
2021-04-01
FB10
Turku University Hospital
Phase 3
Unknown
300 enrolled